DDX59-AS1: A Novel Prognostic Biomarker and Immunotherapy Predictor in Lung Adenocarcinoma
A significant correlation was observed between elevated DDX59-AS1 expression in patients with LUAD and adverse prognosis, alongside increased immune infiltration. These results indicate that DDX59-AS1 may function as a prognostic marker for LUAD and a potential predictor of immunotherapy response.
Authors
- Zhang Li-xi
- Wei Li (ORCID: https://orcid.org/0000-0003-1249-8945)
- Su Wei (ORCID: https://orcid.org/0000-0002-4389-3166)
- Dongbing Li (ORCID: https://orcid.org/0000-0002-5227-9643)
- Xu Qi (ORCID: https://orcid.org/0000-0002-8381-8515)
- Yanli Wang
Institutions
- Beijing Zhongke Science and Technology (China) (CN)
- Lishui City People's Hospital (CN)
- Southeast University (CN)
- Nanjing Medical University (CN)
Publication Details
- Journal
- Current Medicinal Chemistry
- Published
- 2025-02-20
- DOI
- https://doi.org/10.2174/0109298673359149250212073143
- Primary Topic
- RNA modifications and cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.00